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INTRODUCTION
Scientific and practical studies of recent years indicate the 
wide prevalence of functional gastrointestinal disorders, 
as one of the most pressing problems of modern pediatric 
gastroenterology [1].
Functional disorders of the gallbladder and Оddi’s sphincter 
are put down to functional disorders of the biliary system in 
children according to the Rome IV consensus the functional 
gastrointestinal disorders (2016) [1]. The acuteness of the 
problem of functional disorders of the gallbladder and Оddi’s 
sphincter in Pediatric Gastroenterology is stipulated by the high 
prevalence and the possibility of transition to biliary system’s 
organic pathology [2; 3]. The functioning of the gallbladder and 
Оddi’s sphincteris is carried out due to the humoral effect of 
secretin, cholecystokinin [4]. Regulation of the production of 
these substances is performed by microRNA [5]. MicroRNA 
(miRNA, miR) are small non – coding RNA molecules of 21-23 
nucleotides that regulate gene expression at the post-transcrip-
tion level by RNA interference and indirectly they participate 
in protein synthesis, cell differentiation, and tissue [6].
In recent years, there is evidence of association of am-
plification or inhibition of microRNA generation with 
dysfunction and development of the biliary system’s dis-
eases [5; 7; 8].
Ursodeoxycholic acid (UDCA) is a tertiary bile acid that 
is formed in hepatocytes and intestinal cells. Ursodeoxy-
cholic acid has hepatoprotective, anti-cholestatic, litholytic 
cytoprotective, antifibrotic, anti-apoptotic, antioxidant, 
immunomodulating effects. The results of numerous 
scientific studies confirm the positive therapeutic effect 
of ursodeoxycholic acid preparations in diseases of the 
digestive system [9; 10]. Recently, scientists have paid con-
siderable attention to determining the effect of UDCA on 
the expression of various microRNAs [8; 11; 12]. However, 
the effect of ursodeoxycholic acid on the expression profile 
of microRNA in functional disorders of the gallbladder and 
Oddi’s sphincter in children has not been determined yet.
THE AIM
Objective: to study the effect of choleretic therapy on the 
level of microRNA expression in functional disorders of 
the gallbladder and Oddi’s sphincter in children.
MATERIALS AND METHODS
The comprehensive survey of 90 children aged 4 to 14 
years was conducted according to the Rome IV consensus 
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ABSTRACT
The alm: To study the effect of choleretic therapy on the level of microRNA expression in functional disorders of the gallbladder and Oddi’s sphincter in children. 
Materials and methods: Fifty patients with functional disorders of the gallbladder and Oddi’s sphincter who received standard therapy in combination with ursodeoxycholic acid, 
20 patients – standard therapy without ursodeoxycholic acid, and 20 healthy children were examined. The level of expression of microRNA-378f, microRNA-4311, microRNA-4714-
3p in the blood serum by the method of real-time polymerase chain reaction with reverse transcription according to the protocol TaqMan Gene Expression Assays was performed.
Results: It was demonstrated that the activity profile of microRNA-4714-3p was significantly lower in those examined with functional disorders of the gallbladder and Oddi’s 
sphincter than in practically healthy children (p<0.05). After standard therapy combined with ursodeoxycholic acid in children with functional disorders of the gallbladder 
and Oddi’s sphincter, the level of expression of microRNA-378f is significantly higher than before therapy (5.23±0.70 SU and 2.02±0.57 SU respectively) (p<0.05). Against 
the background of standard therapy with the addition of ursodeoxycholic acid or without it, the expression profile of microRNA-4714-3p in the blood serum in children with 
functional disorders of the gallbladder and Oddi’s sphincter significantly decreased (1.93±0.58 SU and 1,14±0,53 SU respectively) (p<0.05). 
Conclusions: Ursodeoxycholic acid in children with functional disorders of the gallbladder and Oddi’s sphincter affects the activity of generation of gene regulators of the cellular 
mechanisms of microRNA-378f and microRNA-4714-3p.
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the functional gastrointestinal disorders (2016) on the 
basis of the municipal institution “Dnipro city clinical 
hospital №1” Dnipro city Council, Dnipro city, Ukraine. 
70 patients showed clinical signs of functional disorders 
of the gallbladder and Oddi’s sphincter [1]. Verification of 
diagnosis and provision of medical care to patients were 
carried out in accordance with the order of the Ministry 
of Health of Ukraine dated 29.01.2013 № 59 “On approval 
of unified clinical protocols of medical care for children 
with diseases of the digestive system” [3]. The research was 
conducted in accordance with the principles of the Helsinki 
Declaration and with the informed consent of the patient’s 
parents or guardians.
Patients with functional disorders of the gallbladder and 
Oddi’s sphincter by simple randomization were divided 
into two groups. The first (1st, main) group was represented 
by 50 patients with functional disorders of the gallbladder 
and Oddi’s sphincter. They received standard therapy in 
accordance with the provisions of the order of the Ministry 
of Health of Ukraine dated 29.01.2013 №59 in combination 
with ursodeoxycholic acid, which was prescribed at the rate 
of 10-15 mg/kg/day. The second (2nd) group (comparison 
group) included 20 patients with functional disorders of the 
gallbladder and Oddi’s sphincter. They received standard 
therapy in accordance with the provisions of the order of 
the Ministry of Health of Ukraine dated 29.01.2013. № 59 
without ursodeoxycholic acid. The course of treatment was 
4 weeks. The effectiveness of treatment after completion of 
complex therapy for all children was evaluated. The third 
(3rd) group (control group) included 20 healthy children. 
Before treatment and after treatment, the molecular genetic 
study was conducted to determine the level of expression of 
microRNA-378f, microRNA-4311, microRNA-4714-3p in 
blood serum by real-time polymerase chain reaction with 
reverse transcription in children of groups 1 and 2 and 
once in children of group 3. It was performed according 
to the Taq Man Gene Expression Assays Protocol in the 
certified laboratory of the Department of General and 
molecular Pathophysiology of the Institute of Physiology 
after A. A. Bogomolets of NAS of Ukraine (Head – Doctor 
of Medical Science, Professor A. A. Krishtal). The study 
included the following steps: isolation of total RNA from 
the primary material (blood serum); isolation of DNA from 
the primary material (blood serum); reverse transcription; 
polymerase chain reaction (PCR); restriction analysis; 
polymerase-chain reaction in real time; calculation of the 
number of amphilic molecules and construction of the 
calibration curve. 
Statistical analysis of the results was carried out using the 
program “STATISTICA 6.1” (№ AGAR909E415822FA). 
Depending on the test results, parametric and nonpara-
metric methods of statistics were used. Differences between 
the signs were considered statistically significant at p<0.05.
RESULTS
The average age of children who received standard therapy 
in combination with ursodeoxycholic acid was 7.84±0.39 
years, without ursodeoxycholic acid – 8.90±0.52 years, 
practically healthy children – 8.15±0.60 years (p>0.05). No 
statistically significant differences were found in the study 
groups by age and gender (p>0.05). In the majority of the 
examined children (57.1%), clinical signs of functional 
disorders of the gallbladder and Oddi’s sphincter were 
repeated. The duration of the disease in patients of the first 
and second groups ranged from 1 to 5 years.
During the study, family aggregation of biliary tract pa-
thology in children’s pedigrees with functional disorders 
of the gallbladder and Oddi’s sphincter was determined. 
The burdened hereditary history of functional disorders of 
the gallbladder and Oddi’s sphincter, chronic cholecystitis 
and cholelithiasis was found in 63 children (90%) of the 
first and second groups of the study.
Contributing factors to the onset or exacerbation of the 
disease in patients with functional disorders of the gallblad-
der and Oddi’s sphincter were eating disorders (in 36 (72%) 
children of the main group and in 16 (80%) patients of the 
comparison group), psychoemotional load (25 (50%) and 8 
(40%), respectively), hypodynamic lifestyle (15 (30%) and 
25 (50%), respectively) and the presence of foci of chronic 
infection (7 (14%) and 4 (20%), respectively) (p>0.05). 
All patients of both groups of observation were admitted 
to the hospital with manifestations of abdominal pain, 
dyspeptic and asthenovegetative syndromes of different 
duration and severity. 28 (56%) children of the first group 
and 13 (65%) patients of the second group complained of 
recurrent pain in the epigastrium and right hypochondrium, 
13 (26%) children of the 1st group and 3 (15%) examined 
2nd group – for recurrent pain in the umbilical region, 9 
(18%) patients of the main group and 4 (20%) children of 
the comparison group – for pain in the right hypochondrium 
at the beginning of the observation (p>0.05). Pain was ob-
served in the right hypochondrium in 42 (84%) children of 
the first group and in 18 (90%) patients of the second group 
on palpation of the abdomen (p>0.05). Dyspeptic symptoms 
were presented with nausea (22 (44%) patients of the main 
group and 8 (40%) of the comparison group), loss of appe-
tite (26 (52%) and 9 (45%) respectively), belching bitter (11 
(22%) and 4 (20%), respectively) before treatment (p>0.05). 
34 (68%) patients of the 1st group and 14 (70%) children of 
the 2nd group had increased fatigue, decreased performance, 
and general weakness before treatment (p>0.05).
Significant differences in the regression of the main 
symptoms of abdominal pain, dyspeptic and astenoveg-
etative syndromes in children of the main group and the 
comparison group were established after the treatment. 
Thus, symptoms of pain remained after treatment in 7 
(14%) children of the first group and in 8 (40%) patients of 
the second group (p<0.05). All children of the main group 
after treatment with UDCA disappeared signs of dyspeptic 
syndrome. In 3 (15%) patients of the comparison group, 
after treatment without UDCA, complaints of nausea and 
decreased appetite persisted. In 9 (18%) patients of the 1st 
group and in 11 (55%) children of the 2nd group symptoms 
of the asthenovegetative syndrome were observed after the 
treatment (p<0.05).
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The cholestasis markers of the biochemical hepatogram 
(alkaline phosphatase, aspartate aminotransferase, alanine 
aminotransferase) in patients with functional disorders 
of the gallbladder and Oddi’s sphincter before treatment 
were significantly higher than those in healthy children 
(p>0.05) (table 1).
A significant decrease in the levels of alkaline phospha-
tase, aspartate aminotransferase, alanine aminotransferase 
in children with functional disorders of the gallbladder and 
Oddi’s sphincter was found when analyzing the dynamics 
of biochemical hepatogram indicators after complex ther-
apy using ursodeoxycholic acid. In children, who did not 
receive UDCA therapy, the above indicators did not have 
significant changes.
A significant decrease in the dynamic contractility of the 
gallbladder found in patients with functional disorders of 
the gallbladder and Oddi’s sphincter both groups when 
studying the data of transabdominal dynamic ultrasound 
before therapy. The contractility of the gallbladder was 
23.44±1.56% in children of the 1st group before treatment 
and 23.75 ± 2.29% in children of the 2nd group (p>0.05). 
The indicators of both groups were significantly lower than 
in practically healthy children – 49.55±1.11% (p<0.05).
The contractility of the gallbladder significantly increased 
to 45.56±1.68% compared in patients of the first group 
with the pre-treatment index (p<0.05). The contractility 
of the gallbladder averaged 29.69 ± 2.99% in children of 
the second group after treatment without UDCA and did 
not have a significant difference from the indicator before 
therapy (p>0.05).
The results of molecular genetic studies of serum expres-
sion of micro-RNA before and after treatment in children 
with functional disorders of the gallbladder and Oddi’s 
sphincter and in healthy children are presented in table 2.
It was found that the parameters of the main group and 
the comparison group did not differ statistically signifi-
cantly (p>0.05) during studying of the level of expression 
of microRNA-378f, microRNA-4311, microRNA-4714-3p 
in serum before treatment in children with functional 
disorders of the gallbladder and Oddi’s sphincter.
It was determined that the activity profile of microR-
NA-4714-3p in the examined groups 1st and 2nd with 
functional disorders of the gallbladder and Oddi’s sphincter 
was significantly lower than in healthy children in the anal-
ysis of the results of molecular genetic research (p<0.05).
However, there was no statistically significant difference 









treatment 507,92±19,94 * 34,96±1,31 * 18,76±0,91 *
After
treatment 359,53±16,59 * ** 26,18±0,97 ** 14,96±0,64 **
Children who did 
not receive UDCA 
(n=20)
Before
treatment 542,85±40,95 * 28,20±1,31 * 17,35±1,52
After
treatment 499,50±40,16 * 29,65±1,66 * 15,90±1,22
Practically healthy children (n=20) 202,95±9,07 24,20±0,89 14,50±0,57
Notes: * – p<0.05 – significantly compared with the parameter value in healthy children; 
** – p<0.05 – significantly compared with the parameter value before treatmen.
Table 2. Results of the study of level serum expression of microRNA in children with functional disorders of the gallbladder and Oddi’s sphincter before 
and after treatment (M±m)
Children’s group
Level expression of microRNA
MicroRNA-378f, SU MicroRNA-4311, SU Micro-RNA-4714-3p, SU
Children who received 
UDCA (n=50)
Before
treatment 2,02±0,57 1,48±0,35 5,56±1,50*
After
treatment 5,23±0,70 ** 1,17±0,18 1,93±0,58*  **
Children who did not 
receive UDCA (n=20)
Before
treatment 2,08±0,96 1,58±0,47 4,66±1,57*
After
treatment 4,49±0,79 1,85±0,88 1,14±0,53*  **
Practically healthy children (n=20) 5,05±2,85 3,07±1,41 53,62±10,42
Notes: * – p<0.05 – significantly compared with the parameter value in healthy children; 
** – p<0.05 – significantly compared with the parameter value before treatmen.
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with the indicators in practically healthy children in the 
study of the level of expression of microRNA-378f and 
microRNA-4311 in children with functional disorders 
of the gallbladder and Oddi’s sphincter before treatment 
(p>0.05).
Correlation analysis showed that the level of expression 
of microRNA-4714-3p in serum before therapy in the 
examined children positively correlated with a decrease 
in the contractile function of the gallbladder according to 
ultrasound examination (r=+0.36; p<0,05).
During the investigation it was established that the 
dynamics of the activity profiles of microRNA-378f and 
microRNA-4714-3p differed significantly after the thera-
py (table 1). After standard therapy in combination with 
ursodeoxycholic acid in children with functional disorders 
of the gallbladder and Oddi’s sphincter, the level of expres-
sion of microRNA-378f approached the value of 5.23±0.70 
SU, which was significantly higher than before therapy in 
children of this group (p<0.05). At the same time, after 
standard therapy alone without ursodeoxycholic acid, 
the level of microRNA-378f expression in children of the 
comparison group did not differ significantly from the 
pre-treatment index (p>0.05).
Against the background of standard therapy with the 
addition of ursodeoxycholic acid and without it, the 
expression profile of microRNA-4714-3p in serum of 
children with functional disorders of the gallbladder and 
Oddi’s sphincter of the 1st and 2nd groups significantly 
decreased to the level of 1.93±0.58 SU and 1.14±0.53 SU 
respectively (p<0.05).
DISCUSSION
When studying the results of the study, positive clinical 
dynamics of manifestations of functional disorders of the 
gallbladder and Oddi’s sphincter was determined after 
complex therapy with the use of ursodeoxycholic acid. This 
fact can be explained by an improvement in the rheological 
properties of bile and a decrease in the concentration of 
primary and secondary bile acids under the influence of 
ursodeoxycholic acid.
As a result of the study, it was found that at the beginning 
of observation of patients with functional disorders of 
the gallbladder and Oddi’s sphincter, the average levels of 
expression of microRNA-378f, microRNA-4311, microR-
NA-4714-3p in serum of children of the main group and 
the comparison group were identical. It can be assumed 
that the significant decrease in the expression profile of 
microRNA-4714-3p before treatment in children of both 
groups was associated with the decrease in the contractile 
function of the gallbladder in children with functional 
disorders of the gallbladder and Oddi’s sphincter.
Analysis of the study data showed that after complex 
therapy with and without ursodeoxycholic acid in children 
with functional disorders of the gallbladder and Oddi’s 
sphincter, the dynamics of levels of expression of microR-
NA-378f and microRNA-4714-3p differed significantly. 
Probably, the significant increase in the expression profile 
of microRNA-378f, which was observed after the course 
of treatment with ursodeoxycholic acid, contributed to 
the restoration of bile drainage. It is possible that the de-
crease in the expression of microRNA4714-3p, which was 
observed after the course of treatment regardless of the 
use of ursodeoxycholic acid, may be due to modification 
of the diet.
CONCLUSIONS
1.  As the result of studies it was found that in children 
with functional disorders of the gallbladder and Oddi’s 
sphincter, changes in the profile of micro-RNA expres-
sion are observed.
2.  These molecular genetic studies indicate the unique 
property of ursodeoxycholic acid in children with func-
tional disorders of the gallbladder and Oddi’s sphincter 
to influence the activity of the generation of gene reg-
ulators of cellular mechanisms of microRNA-378f and 
microRNA-4714-3p.
3.  The use of ursodeoxycholic acid in the treatment of func-
tional disorders of the gallbladder and Oddi’s sphincter 
in children is justified due to its high efficiency.
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